P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC

R. Zinner; S. Cowan; C. Solomides; D.C. Hooper; L. Harshyne; G. Lu-Yao; H. Yang; L. Phan; D. Poller; B. Leiby; M. Werner-Wasik; B. Lu; J. Johnson; R. Axelrod; A. Argiris; N. Evans

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC

【24h】

P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC

机译：P3.17-22 Nivolumab Plus顺铂/ Pemetrexed或Cisplatin / Gemcitabine作为可重型NSCLC的归纳

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2018年第10期|共2页
作者
R. Zinner; S. Cowan; C. Solomides; D.C. Hooper; L. Harshyne; G. Lu-Yao; H. Yang; L. Phan; D. Poller; B. Leiby; M. Werner-Wasik; B. Lu; J. Johnson; R. Axelrod; A. Argiris; N. Evans;
展开▼
作者单位

Medical Oncology Thomas Jefferson University Philadelphia;

Surgical Oncology Thomas Jefferson University Philadelphia;

Pathology Thomas Jefferson University Philadelphia;

Cell Biology Thomas Jefferson University Philadelphia;

Neurosurgery Thomas Jefferson University Philadelphia;

Medical Oncology Thomas Jefferson University Philadelphia;

Medical Oncology Thomas Jefferson University Philadelphia;

Medical Oncology Thomas Jefferson University Philadelphia;

Medical Oncology Thomas Jefferson University Philadelphia;

Phamacology and Experimental Therapeutics Philadelphia Philadelphia;

Radiation Oncology Thomas Jefferson University Philadelphia;

Radiation Oncology Thomas Jefferson University Philadelphia;

Medical Oncology Thomas Jefferson University Philadelphia;

Medical Oncology Thomas Jefferson University Philadelphia;

Medical Oncology Thomas Jefferson University Philadelphia;

Surgical Oncology Thomas Jefferson University Philadelphia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Comparative Study of Gemcitabine Plus Cisplatin and Gemcitabine Plus Fluorouracil in the Treatment of Advanced Pancreatic Cancer [J] . YongqionShu, LiankeLiu, LinxiangLiu, 中国肿瘤临床：英文版 . 2004,第001期
2. Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase Ⅱ open-label clinical study [J] . Shanshan Qin, Jie Qiao, Yu Feng, 中国癌症研究（英文版） . 2019,第002期
3. Comparison of intra-pleural injection efficacy between Endostar and Bevacizumab combined with pemetrexed/cisplatin for the treatment of malignant pleural effusion in patients with epidermal growth factor receptor-/anaplastic lymphoma kinase-lung adenocarci [J] . Yi Cheng, Nan Huang, Kai Qin, 肿瘤学与转化医学（英文） . 2019,第002期
4. P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC [J] . R. Zinner, S. Cowan, C. Solomides, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：P3.17-22 Nivolumab Plus顺铂/ Pemetrexed或Cisplatin / Gemcitabine作为可重型NSCLC的归纳
5. Take-home message in times of crisis: Is it really better to treat with cisplatin & pemetrexed than cisplatin & gemcitabine in first line NSCLC? The power of statistical considerations [J] . Rolfo Christian, Castanon Eduardo Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2015,第3期

机译：危机时刻的重要信息：在第一线NSCLC中，顺铂和培美曲塞治疗是否真的比顺铂和吉西他滨治疗好？统计考虑的力量
6. 1231 A phase I study of axitinib (AG-013736) combined with paclitaxel/carboplatin (P/C), gemcitabine/cisplatin (Gem/Cis) or pemetrexed/cisplatin (Pem/Cis) in patients (pts) with solid tumours, including advanced non-small cell lung cancer (NSCLC) [J] . M.F.Kozloff, L.P.Martin, M.Krzakowski, European Journal of Cancer Supplements . 2009,第2期

机译：1231对阿西替尼（AG-013736）与紫杉醇/卡铂（P / C），吉西他滨/顺铂（Gem / Cis）或培美曲塞/顺铂（Pem / Cis）结合的实体瘤患者（pts）进行的I期研究晚期非小细胞肺癌（NSCLC）
7. Gemcitabine + Cisplatin Combination Electrochemotherapy for Triple Negative Breast Cancers: An in vitro Model Study [C] . R. Sundararajan, V. Raman, V. Masterson World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food Environmental Technologies . 2016

机译：Gemcitabine +顺铂组合电化学疗法三重阴性乳腺癌：体外模型研究
8. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
9. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup [O] . Pilar Garrido, Nadia Chouaki, Monika Serke, 2017

机译：培美曲塞-顺铂诱导后不可切除的局部晚期非鳞状非小细胞肺癌患者的培美曲塞-顺铂合并胸腔放疗：按年龄分组
10. PCN101 A Cost-Effectiveness Analysis of Cisplatin Plus Pemetrexed Doublet Induction Treatment Followed by Pemetrexed Maintenance Compared with Bevacizumab Plus Cisplatin Plus Gemcitabine Triplet Induction Treatment Followed by Bevacizumab Maintenance for Non-Squamous NSCLC in Sweden [O] . Bryden P.A., Kumar G., Winfree K.B., 2013

机译：PCN101对瑞典非鳞状NSCLC进行顺铂加培美曲塞双线诱导治疗后培美曲塞维持治疗与贝伐单抗加顺铂加吉西他滨三线诱导治疗后贝伐单抗维持治疗的成本-效果分析

P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC

著录项

相似文献

相关主题

期刊订阅